ERBB2 and breast carcinoma: TNBC remains one of the most challenging breast cancer subtypes to treat, mainly due to its intrinsic cellular heterogeneity, the absence of key actionable endocrine or HER2 targets, and a propensity for early recurrence and metastasis.